Comment on "The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticarial": reply from authors

Creative Commons License

ACER E., KAYA ERDOĞAN H., Canakci N. Y., SARAÇOĞLU Z. N.

CUTANEOUS AND OCULAR TOXICOLOGY, cilt.39, sa.2, ss.171, 2020 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 39 Sayı: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/15569527.2020.1743304
  • Dergi Adı: CUTANEOUS AND OCULAR TOXICOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, Environment Index, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.171
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

We read Cosansu's commentary entitled "Effectiveness of the new inflammatory parameters in patients with chronic spontaneous urticarial" to our study with great interest. The author remarked that a limited number of patients had C-reactive protein levels and it was not specified whether there were any other drugs used by the patients and no information was given about the severity of the disease in our study.